Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly e...

Related Keywords

United Kingdom ,Montreal ,Quebec ,Canada ,Dallas ,Texas ,United States ,Carolyn Hawley ,Elsa Rossignol ,Hayleigh Collins ,Sukumar Nagendran ,Taysha Gene Therapies Inc ,Regulatory Agency ,Drug Administration ,Company Contact ,Head Of Corporate Communications ,Canale Communications ,European Commission ,Ut Southwestern Gene Therapy Program ,Data Monitoring Committee ,Nasdaq ,Exchange Commission ,Independent Data Monitoring Committee ,Gene Therapies ,Principal Investigator ,Associate Professor Neuroscience ,United States Food ,Investigational New Drug ,Clinical Trial Application ,United Kingdom Medicines ,Responsive Auto Regulatory Element ,Fast Track ,Orphan Drug ,Rare Pediatric Disease ,Gene Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,